Navigation Links
European Neurologists Expect Significant Increases in the Use of Both Tysabri and Extavia in Their Multiple Sclerosis Patients the Next Six Months, According to a Recent Report From BioTrends
Date:12/21/2010

velopment, neurologists appear to have already identified which established DMAs are most at risk with the introduction of these new agents. Knowledge of symptomatic products in development is low with Bayer/Almirall's Sativex and Biogen's Ampyra receiving the highest marks for familiarity, interest and clinical value.

TreatmentTrends®: Multiple Sclerosis in the European Union is a syndicated annual report that provides a comprehensive view of the current and expected future management of MS based on primary research fielded with 229 neurologists in the U.K., France, Germany, Italy and Spain. These reports cover the use of DMAs for the treatment of MS, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use. In addition, respondents were queried about their awareness of and interest in MS-related DMA and symptomatic products in development. A parallel report covering the U.S. market was published in late November.

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc. Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Md. , May 22, 2015  RegeneRx ... today announced a peer-reviewed publication of the results ... evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for the ... controlled adverse environment (CAE ® ) model.  The ... the results, which were previously disseminated by the ...
(Date:5/22/2015)... BOSTON , May 22, 2015   InspireMD, Inc. ... in stent embolic protection systems ("EPS"), today announced that its ... PARADIGM, lead by principle investigator Prof. Piotr Musialek , ... in Paris, France . PARADIGM, ... pe R cutaneous c A roti D revascularization ...
(Date:5/22/2015)... , May 22, 2015 ... phase clinical research unit with a worldwide reputation ... for its frequent publications in peer reviewed medical ... European stakeholders and regulators in discussions about rules ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... offering of senior notes. The Company intends ... a substantial portion of the outstanding borrowings under its credit ... Pierce, Fenner & Smith Incorporated, BNP Paribas Securities Corp. and ...
... 70,737 patients through institutional databases and medical charts, researchers ... determined that only 20 percent of patients with newly ... factors were screened for HBV infection before starting chemotherapy. ... P. Hwang, MD, MPH, the lead author of the ...
Cached Medicine Technology:Zimmer Holdings, Inc. Announces Offering of Senior Notes 2Patients at Risk for Hepatitis B Are Not Adequately Screened Before Receiving Chemotherapy Leading to the Preventable Reactivation of Hepatitis B Infection 2
(Date:5/22/2015)... West Hollywood, CA (PRWEB) May 22, 2015 ... at Sunset Plaza Dental announces that they ... in cosmetic, restorative and other dental treatments. At ... that interest them. Questions regarding what certain treatments ... can also be covered during this initial appointment. ...
(Date:5/22/2015)... 22, 2015 Medivo, Inc., a leader in ... and Genotype Results in ‘Baby Boomers’ Screened for HCV Following ... Lab Test Database” at Digestive Disease Week, May 16-19, 2015. ... and Analytics team members Carol Smyth, MB; Jason Bhan, MD; ... MSI, along with Nancy Reau, MD from the University of ...
(Date:5/22/2015)... 2015 A Phase 3 French ... Society of Clinical Oncology (ASCO)’s annual meeting at ... for those patients who received bevacizumab in addition ... Bevacizumab (Avastin® Genentech, Inc.) is an antibody that ... already routinely used to treat many other cancers, ...
(Date:5/22/2015)... Jupiter, FL (PRWEB) May 22, 2015 ... Ed Begley, Jr., scheduled to broadcast on Friday, May ... PST, via Discovery Channel. , In this episode Innovations ... companies get back to business quickly through disaster recovery ... NDPTC, a company that works collaboratively to develop and ...
(Date:5/22/2015)... AZ (PRWEB) May 22, 2015 In ... Olympics, Parker and Sons is offering to donate $5 ... installing an AC unit or water softening system. Customers ... behalf; Parker and Sons gets business; and the Special ... , The Special Olympics helps over 4.4 million athletes, ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... Under the scheme 'Assistance for capacity Building', Ministry ... upto a maximum //of Rs. 1.50 crores or ... of emergency facilities of State Hospitals of towns/cities ... with NHAI, Department of Road Transport and Highways ...
... new study by specialists at the Johns Hopkins Children’s ... inner-city children with chronic asthma //gets enough medicine to ... reported in December's Pediatrics, are disturbing, the researchers say, ... 'rescue' drugs after an asthma attack strikes and to ...
... women in Scotland wait for weeks to find out if ... of the Scotland's screening //services in meeting the basic deadlines ... east of Scotland, where one quarter of those tested did ... covering Tayside and Fife admitted the delay as a usual ...
... American Dental association announced on the 9th of November, urging ... of infant formulation. // ,The dentists are concerned about ... be disastrous as instead of protecting teeth it might permanently ... to weakened bones and even bone cancer boys. ,This ...
... scientists to exploit prevailing drugs, already in use ... impeding cognitive //decline in Alzheimer's disease, has borne ... of scientists' attention, offers promise in its perceived ... a foregone conclusion for patients afflicted with Alzheimer's. ...
... Innovation and Improvement suggested that some patients should be cared ... admitting them in the hospital wards. ,The ... Accident and Emergency (A&E) departments that leads to hospital admissions ... numbers admitted in hospital wards. ,Home ...
Cached Medicine News:Health News:City Kids With Asthma Lose Out on Preventive Treatment 2Health News:Scotland Women Wait For Weeks For Getting Breast Cancer Results 2